Phaseline

Companies › Invivyd

Invivyd: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 1; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VYD2311
Monoclonal antibody targeting SARS-CoV-2 spike protein; blocks viral entry into cells
–Phase 3COVID-19–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06523153VYD2311Phase 1COVID-19Infectious diseaseMay 2025
NCT07298434VYD2311Phase 3COVID-19Infectious diseaseAug 2026
NCT07655180VYD2311Phase 3COVID-19Infectious diseaseAug 2026

From the company's SEC filings

Cash of $160m on 2026-06-30; operating cash outflow about $172m a year; runway about 11 months at that burn, to Jun 2027

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Verrica Pharmaceuticals TCM Biotech International Vivacelle Bio Ansun Biopharma SymBio Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.